Library

By pinki / May 14, 2022

Displaying 1 - 25 of 1,521

Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn

Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn

By: Antonia Coello Novello, MD, MPH, DR.PH

Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn

Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn

By: Antonia Coello Novello, MD, MPH, DR.PH

Physician Leadership and the Urgency of the Moment in Medicine

Physician Leadership and the Urgency of the Moment in Medicine

By: Barbara L. McAneny, MD

By: Gubens, Matthew

CAR-T Cell as Strategy for the Management of Hematologic Malignancies

CAR-T Cell as Strategy for the Management of Hematologic Malignancies

By: Krishna Komanduri, MD

Case Study Molecular Testing

Case Study Molecular Testing

By: Riess, Johnathan MD

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

By: Benjamin Levy, MD

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

By: Alberto Chiappori, MD

ISLB and MCM Symposia

ISLB and MCM Symposia

By: Christian Rolfo, MD, PhD, MBA, Dr.h.c, Ticiana A. Leal, MD

How to Manage Myelodysplasia: Biomarkers and Novel Treatments

How to Manage Myelodysplasia: Biomarkers and Novel Treatments

By: Guillermo Garcia-Manero, MD

Biosimilars as Front-Line Options for Cancer Care

Biosimilars as Front-Line Options for Cancer Care

By: Jorge J. García, PharmD, MS, MHA, MBA, FACHE

Biosimilars Implementation in the US: A Five Year Review

Biosimilars Implementation in the US: A Five Year Review

By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Current Status of Biosimilars and Recent Approvals

Current Status of Biosimilars and Recent Approvals

By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

By: Paul Frankel - PhD

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

By: Paul Frankel, PhD

Immunotherapy in Cancer: Next Generation Biomarkers

Immunotherapy in Cancer: Next Generation Biomarkers

By: Peter Lee, MD

Tumor Biology, Pathology, Novel Diagnostics

Tumor Biology, Pathology, Novel Diagnostics

By: Tianhong “Tina” Li, MD, PhD

Predictive Biomarkers for Immunotherapy - Non-Small Cell Lung Cancer (NSCLC) as a Model of Tumor Heterogeneity

Predictive Biomarkers for Immunotherapy - Non-Small Cell Lung Cancer (NSCLC) as a Model of Tumor Heterogeneity

By: David R. Gandara, MD

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains

By: Jorge J. García, PharmD, MS, MHA, MBA, FACHE

How Far Have We Gone with Biosimilars?

How Far Have We Gone with Biosimilars?

By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains

Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains

By: Jorge J. García, PharmD, MS, MHA, MBA, FACHE

Biosimilars Implementation in the United States: Where Opportunities Remain

Biosimilars Implementation in the United States: Where Opportunities Remain

By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Bladder Cancer Update

Bladder Cancer Update

By: Benjamin Garmezy, MD

Bladder Cancer Update

Bladder Cancer Update

By: Benjamin Garmezy, MD

Bladder and Kidney

Bladder and Kidney

By: Manojkumar Bupathi, MD, MS